Free Trial
→ This high yielding “gold annuity” is starting to move… (From Golden Portfolio) (Ad)tc pixel
NYSEAMERICAN:MTNB

Matinas Biopharma Q1 2026 Earnings Results & Report

Matinas Biopharma logo
$2.87 +0.04 (+1.41%)
As of 10/9/2026 04:10 PM Eastern

Matinas Biopharma reported Q1 2026 earnings on May 8, 2026. The company reported EPS of -$4.50.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Matinas Biopharma EPS Results

Actual EPS
-$4.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 5 quarters

Matinas Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Matinas Biopharma's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Matinas Biopharma Q1 2026 Earnings FAQ

Matinas Biopharma (NYSEAMERICAN:MTNB) reported earnings of -$4.50 per share for Q1 2026. The report was announced on Friday, May 8, 2026.

Matinas Biopharma Earnings Headlines

GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output
September 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3361075/0/en/gh-power-signs-multi-year-hydrogen-offtake-agreement-with-change-energy-for-hamilton-facility-output.html
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
September 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356817/32419/en/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards.html
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
October 10 at 1:00 AM  |  Porter & Company (Ad)
GH Power, Matinas BioPharma join forces to create NYSE-listed clean energy company
July 13, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/gh-power-matinas-biopharma-join-forces-to-create-nyse-listed-clean-energy-company/ar-AA27Plxu
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement ...
July 13, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/matinas-biopharma-announces-strategic-business-combination-with-gh-power-to-create-publicly-traded-advanced-clean-energy-and-green-hydrogen-company-signs-definitive-agreement-to-sell-lnc-platform-1036318373
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
July 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/13/3326126/32419/en/matinas-biopharma-announces-strategic-business-combination-with-gh-power-to-create-publicly-traded-advanced-clean-energy-and-green-hydrogen-company-signs-definitive-agreement-to-se.html
See More Matinas Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Matinas Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Matinas Biopharma and other key companies, straight to your email.

About Matinas Biopharma

Matinas Biopharma (NYSEAMERICAN:MTNB), Inc. is a clinical-stage biotechnology company developing medicines based on its proprietary lipid nanocrystal (LNC) delivery technology. The platform is designed to improve the oral delivery of active pharmaceutical ingredients that may otherwise have limited absorption or require intravenous administration.

The company’s lead program, MAT2203, is an oral formulation of amphotericin B, an antifungal medicine traditionally administered intravenously. Matinas has studied MAT2203 for serious systemic fungal infections, including cryptococcal meningitis, and has evaluated its potential to provide an orally administered alternative with fewer administration-related burdens. The company has also explored additional applications of its LNC platform for delivering other therapeutics, including anti-infective and nucleic acid-based medicines.

Matinas BioPharma is headquartered in the United States and has focused its development activities on addressing significant unmet needs in infectious disease and drug delivery. Its programs remain subject to clinical development and regulatory review, and the company’s pipeline and priorities may change as research progresses.

View Matinas Biopharma Profile
Earnings Tools